Skip to content
Wednesday 12 August 2026London --:--Frankfurt --:--Zurich --:--
NewslettersSearchEN · DE
MorningWire

European business, markets and politics

FTSE 100
10,833.15
-0.10%
DAX
26,331.07
-0.23%
CAC 40
8,674.94
-0.46%
STOXX 50
6,533.99
-0.26%
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
More
GermanyFranceBankingAIEnergyFintechPropertyCapital Markets
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
  • DE
Sunday 05 December 2021 1:42 pm  |  Updated:  Sunday 05 December 2021 1:44 pm

Pfizer accused of funding anti-AstraZeneca information

By: Amy O'Brien

Add as a preferred source on Google
Pfizer CEO Albert Bourla talks during a press conference after a visit at Pfizer vaccine plant in Puurs, Belgium, April 23, 2021. (John Thys /Pool via REUTERS/File Photo)

US drugmaker Pfizer, the world’s dominant Covid vaccine maker, has been accused of funding educational presentations that said its UK rival AstraZeneca was ineffective and even dangerous for some members of the population.

A Channel 4 Dispatches investigation due to be broadcast this week says it has “uncovered evidence” that Pfizer funded a number of educational presentations that were delivered to health professionals across Canada about its mRNA vaccine.

Included in these presentations were slides that listed several disadvantages of the “viral vector” technology that is the basis for the AstraZeneca vaccine, the broadcaster said.

Delivered by speakers who had received funds from Pfizer, the slides said there is a risk of “chromosomal integration and oncogenesis” with such vaccines, which suggests they might turn a healthy cell into a cancerous cell. They also claimed that the AstraZeneca vaccine cannot be used in immunocompromised people.

The claims made about the viral vector vaccine’s disadvatanges originated from a scientific paper written by a group of authors, one of whom had worked for several years in Pfizer’s vaccine division.

Channel 4 Dispatches did not say where it had found the evidence for these claims, and Pfizer denied it “sought to undermine others’ scientific endeavours” .

Professor Sir Andrew Pollard, the director of the Oxford vaccine group that developed the Astra Zeneca vaccine, dismissed the contents of the slides and warned of the dangers of spreading misinformation.

“That would that the vaccine could somehow integrate itself into the genetic material in people, which is not true,” Pollard said.

Read more

ILiAD Biotechnologies Expands Board of Directors and Appoints Chief Business Officer

He said there was “absolutely zero evidence” that the vaccine “would or could” cause cancer, and that it had been given to millions of immunocompromised people and caused on harm.

“There is huge risks of misinformation, because anything that makes people hesitate about being vaccinated can risk their lives,” Pollard warned.

“It can undermine and impact on decisions that people make about their own health, but also create uncertainty for policymakers.”

Pfizer said it “provided funds to a third party agency” for an “education programme” but did “not provide presentation materials … and did not edit or influence the presentations”.

In the same investigation, Channel 4 also reveals an analysis by one biological engineering expert that claims the manufacturing costs of Pfizer’s vaccine stands at just 76p per shot, but it is reportedly being sold for £22 a dose to the UK government.

It’s been an extremely lucrative year for the drugmaker, which now wields considerable political influence due to its hefty contracts with governments around the world.

Pfizer forecast sales of its vaccine will hit $36bn in 2021 – double that of its closest rival Moderna. As of October, the pharma group provided 80 per cent of Covid Vaccines in the EU, and 74 per cent in the US.

Read more

Astrazeneca explores $400bn megadeal with US rival 

AstraZeneca building exterior with logo, glass facade, UK flag, and wildflowers in foreground.

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • News

Categories

  • Business

Related Topics

  • AstraZeneca
  • Vaccine

Trending Articles

  • Martin Williams on his favourite Toast the City venues

  • Cycle Pharmaceuticals Selects Forma Life Sciences to Establish U.S. Commercial Supply for FDA-Approved CAVHANZA™ (nilotinib) Orally Disintegrating Tablets

  • Burnham’s devolution drive could ‘push 90,000 jobs out of London’

  • ‘Absurd’: Government seeks quantum tech chief – no experience necessary

  • BM3EAC Corp. 2026 Semi-Annual Report

More from Morning Wire

  • ILiAD Biotechnologies Expands Board of Directors and Appoints Chief Business Officer

    Business Wire
  • Astrazeneca explores $400bn megadeal with US rival 

    Markets
    AstraZeneca building exterior with logo, glass facade, UK flag, and wildflowers in foreground.
  • Astrazeneca share price tumbles on $400bn megamerger talks

    Investing
    Astrazeneca headquarters with logo, reflecting commitment to reduce US medicine prices after Trump administration pressure
  • Astrazeneca and Jaguar Land Rover given power to endorse talented migrants for visas

    Politics
    Jonathan Reynolds addressing the SMMT's annual International Automotive Summit (image courtesy of SMMT)
  • As it happened: UK stocks cool after Astrazeneca drags; Trump and Iran clash over peace talks

    FTSE 100 Live
    Donald Trump speaking at a desk, gesturing with hands, wearing a dark suit and red tie.
  • Sweeping job cuts at GSK to fund £400m Cambridge campus

    Pharma
    Modern GSK Cambridge campus buildings with sky bridge, green spaces, and people walking and cycling.
  • Barclays in legal battle with MFS administrators over part of £160m holding

    Banking
    Barclays bank exterior with logo as it announces mortgage rate cuts amidst upcoming interest rate decision.
  • Verdiva Bio Appoints Cardiometabolic Leader Steve Marso as Chief Medical Officer

    Business Wire
MorningWire

Independent European business, markets and political news for decision-makers.

Morning Briefing

Europe

  • Germany
  • France
  • Europe
  • UK & Ireland

Business

  • Markets
  • Banking
  • Technology
  • Energy
  • Property
  • Fintech

Editorial

  • Opinion
  • Editorial Policy
  • Corrections
  • Contact

Company

  • About Morning Wire
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
© 2026 Morning Wire Ltd · Published by Morning Wire Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
Privacy · Terms · Cookies · Facebook